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Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since
the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The
aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve
the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects
previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed
inMPMand healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA.
The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to
the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong
impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease
and the clinical approach to an individualized therapy.
1. Introduction
Malignant mesothelioma is a highly aggressive cancer, unre-
sponsive to chemotherapy, radiotherapy, or surgical resec-
tion. In particular, Malignant Pleural Mesothelioma (MPM)
without treatment is associated with a poor prognosis, with a
median survival ranging from 4 to 10 months [1], but tumor
stage, histology, and type of therapy had a significant effects
on survival [2]. MPM represents less than 1% of known can-
cers but its incidence will continue to increase significantly,
at least until 2019-2020 [1]. This uninterrupted increase in
MPM is consistently attributable to the inhalation of asbestos
fibres.Widespread employment of asbestos in the last century
[3], combined with the high biopersistence of asbestos fibres,
accounts for the extraordinary proportion of people exposed
to asbestos for occupational or environmental reasons. In
fact, about 20–40% of adult men report a work history that
may have entailed asbestos exposure on the job (Helsinki
criteria, 1997).
At this time the only instruments for screening and
early diagnosis are based on radiological tests with evident
ethical and economic problems. For this reason, some authors
are evaluating biological indicators with the significance of
screening and early diagnosis markers, such as serum and
plasmatic osteopontin (OPN) and serum mesothelin-related
proteins (SMRP) [4–8]. However, the clinical limitation
of these studies is that SMRP and pOPN lack sensitivity
and specificity, respectively, limiting their usefulness for
diagnosis and disease therapy monitoring of patients. So,
several researches are evaluating combination of biomarkers
for earlier and better diagnosis of MPM cases.
Very recently, we published a paper on gene expression
in MPM, suggesting TIMP3, THBS2, and MLSN as tumor
genes in MPM [9]. In 2014, we also reported a proteomic
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research, where we highlighted Desmin, Vimentin, and Pre-
Lamin A/C as promising markers for MPM [10].
In the present study, we aim to validate all these markers
founded in our recent studies in serum, alone or in combi-
nation with other interesting markers, in order to identify a
panel of biomarkers useful in the surveillance of high-risk
people.
2. Materials and Methods
2.1. Patients. Serum and plasma were available from 43 sub-
jects previously exposed to asbestos (controls), not affected
by MPM or another neoplasm, presenting at the University
Hospital of Pisa in years 2008–2013, within a follow-up pro-
gram of health surveillance established by the Occupational
Medicine Unit.
The program consists of the following: at the initial
assessment a complete medical examination, including chest
X-ray, spirometry, andDLCO, and analysis ofmesothelin and
osteopontin (ELISA) is carried out.
27 MPM patients were enrolled at the time of diagnosis,
before beginning any therapeutic treatment. All MPMs were
epithelioid types, histologically confirmed.
Each sample was coded at the moment of collection,
in order to avoid any personal identification: all data were
treated in accordance with the Italian law of privacy ( number
675/96) andhandled as approved by the Ethical Board and the
Helsinki declaration.
For all patients, age, sex, smoking habit, years of work,
and asbestos exposure were indicated. For MPM group, the
average number of asbestos exposure was computed for only
the one who was exposed.
2.2. ELISA Analysis. The Human Osteopontin Assay Kit
(IBL, Gunma, Japan), a commercially available ELISA (enz-
yme-linked immunosorbent assay), was used to determine
the level of pOPN. Briefly, plasma samples were diluted 1 : 10
with EIA buffer. Blank, standards, and samples were applied
in duplicate in a O-17 antibody precoated microwell plate
and were incubated for 1 hour at 37∘C. The plate was washed
eight times and 100 l of labeled antibody 10A16 was added in
each well. After an incubation period of 30 minutes at 4∘C,
the plate was washed nine times and chromogen was added.
The plate was incubated for 30 minutes at room temperature
in the dark and stop solution was added. Absorbance read
at 450 nm was used to quantify the OPN concentration in
ng/mL by comparison with the standard curve plotted by
Microsoft Excel.
Serum mesothelin concentration was measured using
a sandwich-type ELISA, Mesomark (Cisbio International,
Gif/Yvette, France), according to instructions [11]. Briefly,
patient serum samples were diluted 1 : 101 with the assay
diluent. Next, 100 l of blank, provided standards, and samples
were applied in duplicate in a microwell plate precoated with
antibody 4H3. After 1-hour incubation on a shaking plate
at room temperature, the wells were washed and antibody
OV569-HRP was added for 1 hour. After a second washing
step, TMB substrate was added to wells for 15 minutes, and
then 100 l of stop solution was added. Absorbance read at
450 nm was used to quantify the SMRP concentration in nM
by comparison of mean of the duplicate measurement with a
calibration curve fitted by CourbesRD software (InstallShield
Corporation, Inc., France).
Cytokines and grow factors were measured using mag-
netic bead multiplex immunoassays (Bio-Plex, BIO-RAD
Laboratories, Milano, Italy). Luminex multiplex panel tech-
nology was used for simultaneous measurement of a panel
of the following analytes: IL6, TNF-a, IL-5, Eotaxin, FGF-
basic, PDGF-bb, VEGF, IP-10, CTACK, HGF, and SCGF-b.
Briefly, 50mL of diluted (1 : 4) serum samples and reaction
standards were added, in duplicate, to a 96 multiwells plate
containing analyte beads followed by incubation for 30
minutes at room temperature. After washing, the antibody-
biotin reporter was added and incubated for 10 minutes
with streptavidin phycoerythrin. The levels of the cytokines
were determined using the Bio-Plex array reader (Luminex,
Austin, TX). The Bio-Plex Manager software optimized the
standard curves automatically and returned the reading data
as Median Fluorescence Intensity (MFI) and concentration
(pg/mL).
Vimentin ELISA kit (MyBioSource, San Diego, Califor-
nia, USA, cat. MBS721933), Desmin ELISA kit (USCN, Busi-
ness Co., Ltd.), THBS2 ELISA kit by MyBioSource (San Di-
ego, California, USA, cat.MBS175793), Fibulin 3 ELISA kit by
USCN (Life Science Inc., cat. E95422Hu), and TIMP3 ELISA
kit by Abcam (cat. Ab119608) were used for quantitative
detection of human Vimentin, Desmin, Thrombospondin,
Fibulin, and Timp3 in serum, respectively, according toman-
ufacturer’s instructions. Briefly, microtiter plates provided in
these kit had been precoatedwith specific antibody. Standards
and samples were then added to the appropriate microtiter
plate wells with a biotin-conjugated specific antibody. After
incubation, wells were washed and then incubated with
HRP enzyme substrate. The reactions were stopped and the
intensity of color was measured at 450 nm in a microplate
reader.
The prelamin A/C concentration in serum samples was
determined by home-made ELISA kit. MaxiSorp 96 micro-
titer plates (Nunc, GmbH,Germany) were coatedwith 100 𝜇L
of prelamin (2.5𝜇g/mL) (Recombinant Human Prelamin
A (number REP0039, Diatheva srl, Fano, Italy) prepared
in carbonate bicarbonate buffer (pH 9.75) and incubated
for 48 hours at room temperature. The coated wells were
blocked with phosphate buffered saline (PBS) containing 3%
bovine serum albumin (BSA, Sigma) for two hours at room
temperature (RT). Plates were then washed with PBS con-
taining 0.1% Tween-20. Welles were incubated with 250 ng
of primary antibody preLMN A/C (Rabbit Anti-Human
Prelamin A (number ANT0045, Diatheva srl, Fano, Italy) in
the presence of serial dilutions preLMN A/C (25–800 ng)
or serum samples for 2 hours at 37∘C. After the incuba-
tion period the wells were decanted, washed five times,
and incubated with 1 : 25000 of the anti-rabbit secondary
antibody, HRP conjugated for 1 hour at 37∘C. Plates were then
washed and incubated with tetramethylbenzidine (TMB), as
the substrate, for 10 minutes at RT. Optical densities (OD)
were measured at 450 nm using a 96-well plate reader ELISA
spectrophotometer (Wallac Victor2 1420 multilabel counter
PerkinELMER).
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2.3. Statistical Analysis. All markers were analyzed to define
the potential Gaussian distribution, in order to choose the
appropriate statistical method, using Kolmogorov-Smirnov
test. Differences between groups were analyzed by Mann–
Whitney test, since the variables were not normally dis-
tributed, and all values were shown as median, 25th, and
75th percentiles. On the other hand, Gaussian variables were
analyzed using Student’s t-test for unpaired samples and
reported as mean plus or minor standard deviation (SD).
Logistic regression was used to determine the weight
given to each marker and then to calculate a specific formula
to provide a combined risk index. In order to estimate
whether thismarker combinationmight increase themarkers
performance in MPM detection, receiver-operating charac-
teristic (ROC) curves were plotted and the areas under curves
(AUC) were calculated with their 95% confidence intervals
(95% CI) using standard techniques to evaluate sensitivity
and specificity of each marker and their combination. The
Youden Index (1 + Sensitivity − (1 − Specificity)) was used
to assess the best cut-off for each marker or marker combina-
tion. The best cut-off was defined as the better combination
of sensitivity and specificity. The index gives equal weight to
false positive and false negative values, so all tests with the
same value of the index give the same proportion of total
misclassified results. Statistical analysis was performed with
SPSS v20.0 (Statistical Package for the Social Sciences).
3. Results
Demographic, smoking habit, and working history data of
people under investigation are shown in Table 1.
Only Eotaxin, VEGF, HGF, Lamin, and Vimentin, since
normally distributed, were reported as mean, standard devi-
ation and minimum and maximum values. These markers
were analyzed with a Student’s t-test. On the contrary, the
other markers were showed as median, 25∘ percentile, and
75∘ percentile, due to their non-Gaussian distribution, and
they were analyzed with nonparametric statistical method
(Mann–Whitney test). All data are shown in Table 2.
All markers differentially expressed in workers previously
exposed to asbestos and MPM cases in statistical analysis
were evaluated with ROC curve (Table 3).
THSP2 was excluded as diagnostic marker because of its
low AUC value. The other markers were analyzed making
several combinations, applying a model of logistic regression
to determine the weight of each marker. As shown in Table 3
by the AUC values, the best markers were IL6 and pOPN, or
SMRPandpOPN. Each of these combinationswas testedwith
all other markers, one at time. The best three-marker combi-
nations were IL6-pOPN-SMRP and IL6-pOPN-Desmin that
reached an AUC value of 0.945 and 0.950, respectively. In
the next step, all the other markers were added one at time
to these two combinations. The resulting best four-marker
combination was the one composed by SMRP, pOPN, IL6,
andVimentin, with anAUCvalue of 0.962 (CI of 0.910–1000),
as show in Figure 1.
Using Youden Index, the best cut-off of this mark-
ers combination was 0.13, with a sensitivity of 100% and
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Figure 1: Biomarkers combinations were graphically shown.
a specificity of 73%. When Desmin and HGF were added to
this combination, at the best cut-off, the specificity reached
85.7%.
4. Discussion
Since the last decade, researches focused their attention on
new diagnostic and/or prognostic biomarkers for MPM.This
tumor is quite rare, but its incidence is increasing, due to the
widespread asbestos use in the world.
In Italy, asbestos was banned in 1992, even if, in other
parts of the world, such as countries from Asia, Africa,
and South-America, asbestos is still employed in several
industries and working processes.
The MPM is a tumor almost paradigmatic from the per-
spective of secondary prevention and early diagnosis. In fact,
its long latency and the possibility to identifying a population
at risk on the basis of previous exposure to asbestos make
it a type of cancer on which to measure the importance of
preventive strategies and health surveillance. Unfortunately,
at present there are no established and unanimously accepted
screening protocols. There is some debate on whether to
perform regularly (and repeatedly) X-ray screening or better
CT scan to the entire population of subjects with a past
exposure to asbestos. In fact, it raises the ethical problem of
exposure to nonnegligible doses of ionizing radiation.
In order to evolve a more reliable and less invasive
protocol for the MPM, ideally, it would be desirable to
identify biomarkers that allow an early diagnosis. These
biomarkers could allow the identification of a grading of
risk for MPM (thus allowing the modulation of the amount
of radiological exams) and may increase the success of
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Table 1: Concerning controls and MPM, age as median and standard deviation, percentage of males, smoking habit, and years of work as
median and standard deviation.
Age Sex (males) Smoking habit Years of work Asbestosexposure
Years
asbestos exp
Controls (43) 58.7 ± 9.5 100%
30% no smokers
7% current smokers
63% ex-smokers
34.4 ± 6.5 100% 16.9 ± 8.5
MPM (27) 69.4 ± 7.9 78%
30% no smokers
11% current smokers
59% ex-smokers
32.7 ± 9.3 63% 19.5 ± 10.1∗
∗ pertained to asbestos exposed patients.
Table 2: Biomarkers data were reported as mean ± SD (standard deviation) or median and 25∘–75∘ percentile. The 𝑝 value was considered
significant when it was <0.5 (∗).
Marker Unit Subjects Mean ± SD Min Max 𝑝 value
Eotaxin pg/mL WorkersMPM
168.48 ± 74.02
165.70 ± 67.04
36.00
63.40
337.19
322.27 0.875
VEGF pg/mL WorkersMPM
2133.19 ± 6066.87
459.25 ± 541.43
20.60
108.8
30140.00
3013.60 0.79
HGF pg/mL WorkersMPM
337.49 ± 142.40
634.56 ± 436.26
155.83
83.25
832.56
1972.15 0.002
∗
Lamin ng/mL WorkersMPM
4875.15 ± 1723.54
4446.35 ± 1049.46
622.27
2642.23
9856.80
7305.91 0.287
Vimentin ng/mL WorkersMPM
6.26 ± 2.34
8.06 ± 3.79
1.73
1.14
13.18
21.16 0.023
∗
Median 25∘ percentile 75∘ percentile
Timp3 pg/mL WorkersMPM
29.60
27.20
18.41
16.87
41.04
36.43 0.6
THSP2 pg/mL WorkersMPM
21525
12370
15175
8395
26700
21220 0.023
∗
SMRP nM WorkersMPM
0.72
1.35
0.50
0.94
1.15
3.07 0.000
∗
pOPN ng/mL WorkersMPM
225.8
555.0
167.0
249.7
302.6
911.2 0.004
∗
IL6 pg/mL WorkersMPM
11.4
22.81
7.4
14.85
14.8
39.26 0.000
∗
TNFa pg/mL WorkersMPM
28.58
32.65
19.33
22.03
37.91
42.41 0.655
IL5 pg/mL WorkersMPM
6.32
6.91
5.21
4.33
9.96
10.97 0.942
FGF basic pg/mL WorkersMPM
74.85
82.71
51.72
53.90
104.18
115.11 0.534
PDGF-bb pg/mL WorkersMPM
7084.53
5941.01
4095.57
2734.14
9098.03
9309.93 0.591
IP10 pg/mL WorkersMPM
941.15
1565.34
791.68
1122.36
1444.00
2421.65 0.002
∗
CTAK pg/mL WorkersMPM
578.34
566.95
461.75
450.95
780.41
896.65 0.947
SCGFb pg/mL WorkersMPM
56887
47188
28627
37715
77644
61507 0.686
Desmin ng/mL WorkersMPM
48.79
66.05
42.98
47.37
58.78
292.76 0.004
∗
Fibulin ng/mL WorkersMPM
372.94
385.55
251.31
155.87
430.12
533.33 0.983
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Table 3: Roc curve analysis with AUC values of biomarker, alone or in combination.
AUC (IC 95%) AUC of biomarker combination
SMRP HGF pOPN Desmin IP10 Vimentin
IL6 0.880 (0.800–0.961) 0.904 0.821 0.910 0.904 0.869 0.829
SMRP 0.795 (0.688–0.902) — 0.866 0.910 0.837 0.837 0.862
HGF 0.767 (0.644–0.890) — 0.881 0.813 0.804 0.792
pOPN 0.766 (0.597–0.934) — 0.817 0.844 0.844
Desmin 0.739 (0.597–0.881) — 0.731
IP10 0.719 (0.592–0.846) — 0.774
Vimentin 0.685 (0.550–0.820) —
THSP2 0.334 (0.192–0.476)
therapeutic approaches applied at an early stage of the disease.
So, the identification of appropriate serum markers would
lead to a revolution in the management of the surveillance of
high-risk population and also in the possibility of diagnosis
and treatment of patients.
To date, the most important biomarkers in MPM diag-
nosis and prognosis were SMRP and OPN, as shown by
several authors in the research field [4, 6, 12, 13]. However,
their use in the real clinical practice is limited because of
an inadequate diagnostic accuracy. As in any other type
of cancer, a biomarker combination could improve both
sensitivity and specificity. In recent years, SMRP and/or
pOPN were combined with other biomarkers, as CA125,
CEA, andMPF (Megakaryocyte Potentiating Factor) [14–17].
All these combinations were performed using biomarkers
already known for their employment in diagnosis of cancer
different from MPM. Probably for this reason, biomarker
combination did not reach appropriate values of sensitivity
and specificity.
In this study, all the markers employed to make several
combinations were specific for MPM diagnosis, deriving
from very recent studies in mesothelioma field.
In 2014, Giusti et al. [10] performed a comparative
proteomic analysis in MPM where some new proteins were
suggested as potential biomarkers for MPM diagnosis. In
particular the authors evidenced an altered expression of
nuclear lamin and related filament proteins such as Vimentin
and Desmin suggesting their ability to distinguish epithelioid
mesothelioma from other lung malignancies with good val-
ues of sensibility and specificity.
Regarding genetics, very recently, Melaiu et al. [9] pub-
lished a paper on genes differentially expressed in mesothe-
lioma patients compared to healthy pleura, showing that
several genes, including THSP2 and TIMP3, are differentially
expressed between normal pleura and MPM. However, the
expression of the mRNA usually shows a large overlap
between healthy and malignant tissues leading to the idea
that perhaps at mRNA level it is difficult to detect important
differences enabling appropriate AUC for diagnostic discrim-
inations.
After our recent studies using genomic and proteomic
approaches, in the present study, specific ELISA were set
up to validate whether the differentially expressed proteins
were also detectable in the serum. Other markers, such as
SMRP, pOPN, previously shown as diagnostic markers for
MPM, and a panel of cytokines and grow factors (IL6, TNF-
a, IL-5, Eotaxin, FGF-basic, PDGF-bb, VEGF, IP-10, CTACK,
HGF, and SCGF-b) were studied. Antibodies or ELISA kit
were purchased by commercial sources or producedwhennot
commercially available, using commercial antigens or syn-
thetic peptides corresponding to the immunogenic portions
of the identified proteins.
First of all, all markers were explored to evaluate eventual
confounding factors (sex and asbestos exposure) and it is
of relevance to mention that no significant difference of
biomarker serum levels was detectable between female/male
and exposed/not exposed MPM patients.
Then, each marker was analyzed alone, comparing serum
levels of MPM cases and subjects with a previous occu-
pational exposure to asbestos. SMRP, pOPN, IL6, HGF,
Desmin, IP10, Vimentin, and THSP2 were statistically dif-
ferent between the studied groups. Then, using a logistic
regression method, these biomarkers were combined in
several models, involving two, three, four, five, and six
markers. As expected, an implementation of the biomarkers
panel increased both sensitivity and specificity. Indeed, the
combination of six biomarkers (SMRP-pOPN-IL6-Vimentin-
Desmin-HGF) reached a sensitivity of 100% and a specificity
of 85.7% at the best cut-off. Nevertheless, such result needs
a careful interpretation considering the small number of
patients examined. Although in terms of diagnostic efficiency
these results are very interesting, we have to consider two
major limitations. The first one is simply methodological
and derives from the paucity of the cases sample analyzed.
This is, more or less, a common weak-point of any research
on MPM, suggesting the need for higher sized studies
involving multiple research centers. The second limitation is
of epidemiologic order since predictive values of biomarkers
are negatively affected by very low incidence of disease.
This study should be considered as preliminary. In fact,
the number of recruited patients could not allow estab-
lishing a “discovery setting” (that allows the identification
of biomarkers) and a “validation setting” (that allows the
independent validation of the panel). However, we suggest
that the combination ofmultiplemarkers could be very useful
rather than the use of singlemarkers in the diagnosis ofMPM.
Further studies are needed to validate these very promising
results.
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